Mesterolone
![]() | |
Clinical data | |
---|---|
Trade names | Proviron, others |
Other names | NSC-75054; SH-60723; SH-723; 1 |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 3% |
Protein binding | 98% (40% to Albumin, 58% to SHBG) |
Metabolism | Liver |
Elimination half-life | 12-13 hours |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.014.397 |
Chemical and physical data | |
Formula | C20H32O2 |
Molar mass | 304.474 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Mesterolone, sold under the brand name Proviron among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels.[2][3] It has also been used to treat male infertility, although this use is controversial.[2][4][5] It is taken by mouth.[2]
Side effects of mesterolone include symptoms of masculinization like acne, scalp hair loss, increased body hair growth, voice changes, and increased sexual desire.[2] It has no risk of liver damage.[2][3] The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT).[2][6] It has strong androgenic effects and weak anabolic effects, which make it useful for producing masculinization.[2] The drug has no estrogenic effects.[2][3]
Mesterolone was first described by 1966[7] and introduced for medical use by 1967.[8][9] In addition to its medical use, mesterolone has been used to improve physique and performance, although it is not commonly used for such purposes due to its weak anabolic effects.[2] The drug is a controlled substance in many countries and so non-medical use is generally illicit.[2][10]
Medical uses
[edit]Mesterolone is used in the treatment of androgen deficiency in male hypogonadism, anemia, and to support male fertility among other indications.[2][11][12] It has also been used to treat delayed puberty in boys.[13] Because it lacks estrogenic effects, mesterolone may be indicated for treating cases of androgen deficiency in which breast tenderness or gynecomastia is also present.[14] The drug is described as a relatively weak androgen with partial activity and is rarely used for the purpose of androgen replacement therapy, but is still widely used in medicine.[2][12][15][3]
Mesterolone is used in androgen replacement therapy at a dosage of 50 to 100 mg 2 to 3 times per day.[16]
Route | Medication | Major brand names | Form | Dosage |
---|---|---|---|---|
Oral | Testosteronea | – | Tablet | 400–800 mg/day (in divided doses) |
Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg/2–4x day (with meals) | |
Methyltestosteroneb | Android, Metandren, Testred | Tablet | 10–50 mg/day | |
Fluoxymesteroneb | Halotestin, Ora-Testryl, Ultandren | Tablet | 5–20 mg/day | |
Metandienoneb | Dianabol | Tablet | 5–15 mg/day | |
Mesteroloneb | Proviron | Tablet | 25–150 mg/day | |
Sublingual | Testosteroneb | Testoral | Tablet | 5–10 mg 1–4x/day |
Methyltestosteroneb | Metandren, Oreton Methyl | Tablet | 10–30 mg/day | |
Buccal | Testosterone | Striant | Tablet | 30 mg 2x/day |
Methyltestosteroneb | Metandren, Oreton Methyl | Tablet | 5–25 mg/day | |
Transdermal | Testosterone | AndroGel, Testim, TestoGel | Gel | 25–125 mg/day |
Androderm, AndroPatch, TestoPatch | Non-scrotal patch | 2.5–15 mg/day | ||
Testoderm | Scrotal patch | 4–6 mg/day | ||
Axiron | Axillary solution | 30–120 mg/day | ||
Androstanolone (DHT) | Andractim | Gel | 100–250 mg/day | |
Rectal | Testosterone | Rektandron, Testosteronb | Suppository | 40 mg 2–3x/day |
Injection (IM or SC ) | Testosterone | Andronaq, Sterotate, Virosterone | Aqueous suspension | 10–50 mg 2–3x/week |
Testosterone propionateb | Testoviron | Oil solution | 10–50 mg 2–3x/week | |
Testosterone enanthate | Delatestryl | Oil solution | 50–250 mg 1x/1–4 weeks | |
Xyosted | Auto-injector | 50–100 mg 1x/week | ||
Testosterone cypionate | Depo-Testosterone | Oil solution | 50–250 mg 1x/1–4 weeks | |
Testosterone isobutyrate | Agovirin Depot | Aqueous suspension | 50–100 mg 1x/1–2 weeks | |
Testosterone phenylacetateb | Perandren, Androject | Oil solution | 50–200 mg 1x/3–5 weeks | |
Mixed testosterone esters | Sustanon 100, Sustanon 250 | Oil solution | 50–250 mg 1x/2–4 weeks | |
Testosterone undecanoate | Aveed, Nebido | Oil solution | 750–1,000 mg 1x/10–14 weeks | |
Testosterone buciclatea | – | Aqueous suspension | 600–1,000 mg 1x/12–20 weeks | |
Implant | Testosterone | Testopel | Pellet | 150–1,200 mg/3–6 months |
Notes: Men produce about 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes: a = Never marketed. b = No longer used and/or no longer marketed. Sources: See template. |
Non-medical uses
[edit]Mesterolone has been used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters.[2]
Side effects
[edit]Side effects of mesterolone include virilization among others.[2]
Pharmacology
[edit]Pharmacodynamics
[edit]Like other AAS, mesterolone is an agonist of the androgen receptor (AR).[2] Mesterolone is described as a very poor anabolic agent due to inactivation by 3
Mesterolone is not a substrate for 5
Mesterolone is not a substrate for aromatase, and so cannot be converted into an estrogen.[2] As such, it has no propensity for producing estrogenic side effects such as gynecomastia and fluid retention.[2] It also has no progestogenic activity.[2]
Because mesterolone is not 17
Pharmacokinetics
[edit]The C1
Chemistry
[edit]Mesterolone, also known as 1
History
[edit]Mesterolone was developed in the 1960s[22] and was first described by 1966.[7][23][24][25] It was introduced for medical use by Schering under the brand name Proviron by 1967.[8][9] The well-established brand name Proviron had previously been used by Schering for testosterone propionate starting in 1936.[26] Following the introduction of mesterolone as Proviron, Schering continued to market testosterone propionate under the brand name Testoviron.[26] A number of sources incorrectly state that mesterolone was synthesized or introduced for medical use in 1934.[22][2][27][28]
Society and culture
[edit]Generic names
[edit]Mesterolone is the generic name of the drug and its INN , USAN , BAN , and DCIT , while mestérolone is its DCF .[19][20][29][30]
Brand names
[edit]Mesterolone is marketed mainly under the brand name Proviron.[19][20][30][2]
Availability
[edit]Mesterolone is available widely throughout the world, including in the United Kingdom, Australia, and South Africa, as well as many non-English-speaking countries.[20][30] It is not available in the United States, Canada, or New Zealand.[20][30] The drug has never been marketed in the United States.[27]
Legal status
[edit]Mesterolone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act.[10][31]
Research
[edit]In one small scale clinical trial of depressed patients, an improvement of symptoms which included anxiety, lack of drive and desire was observed.[32] In patients with dysthymia, unipolar, and bipolar depression significant improvement was observed.[32] In this series of studies, mesterolone lead to a significant decrease in luteinizing hormone and testosterone levels.[32] In another study, 100 mg mesterolone cipionate was administered twice monthly.[33] With regards to plasma testosterone levels, there was no difference between the treated versus untreated group, and baseline luteinizing hormone levels were minimally affected.[33]
References
[edit]- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-15.
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 641–. ISBN 978-0-9828280-1-4.
- ^ a b c d Nieschlag E, Behre HM (1 April 2004). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 411–. ISBN 978-1-139-45221-2.
- ^ Hargreave TB (6 December 2012). Male Infertility. Springer Science & Business Media. pp. 398–399. ISBN 978-1-4471-1029-3.
- ^ Lipshultz LI, Howards SS, Niederberger CS (24 September 2009). Infertility in the Male. Cambridge University Press. pp. 445–446. ISBN 978-0-521-87289-8.
- ^ Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC 2439524. PMID 18500378.
- ^ a b Behre HM, Wang C, Handelsman DJ, Nieschlag E (2004). "Pharmacology of testosterone preparations". Testosterone. Cambridge University Press. pp. 405–444. doi:10.1017/CBO9780511545221.015. ISBN 9780521833806.
- ^ a b Rausch-Stroomann JG, Petry R, Hienz HA (1967). "The influence of mesterolone on testicular function". Research on Steroids. 3. Pergamon: 181–184.
- ^ a b Tausk M (1968). "Practically Applicable Results of Twenty Years of Research in Endocrinology". Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Vol. 12. pp. 137–164. doi:10.1007/978-3-0348-7065-8_3. ISBN 978-3-0348-7067-2. PMID 4307936.
{{cite book}}
:|journal=
ignored (help) - ^ a b Karch SB (21 December 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 30–. ISBN 978-1-4200-0346-8.
- ^ Allahbadia GN, Das RB (12 November 2004). The Art and Science of Assisted Reproductive Techniques. CRC Press. pp. 824–. ISBN 978-0-203-64051-7.
- ^ a b Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1186–. ISBN 978-0-7817-1750-2.
- ^ Hart I, Newton RW (6 December 2012). Endocrinology. Springer Science & Business Media. pp. 119–. ISBN 978-94-010-9298-2.
- ^ Corona G, Rastrelli G, Vignozzi L, Maggi M (June 2012). "Emerging medication for the treatment of male hypogonadism". Expert Opinion on Emerging Drugs. 17 (2): 239–259. doi:10.1517/14728214.2012.683411. PMID 22612692. S2CID 22068249.
- ^ Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, et al. (2004). "Testosterone replacement therapy: current trends and future directions". Human Reproduction Update. 10 (5): 409–419. doi:10.1093/humupd/dmh035. PMID 15297434.
- ^ Rastrelli G, Reisman Y, Ferri S, Prontera O, Sforza A, Maggi M, Corona G (2019). "Testosterone Replacement Therapy". Sexual Medicine. Springer. pp. 79–93. doi:10.1007/978-981-13-1226-7_8. ISBN 978-981-13-1225-0.
- ^ Saartok T, Dahlberg E, Gustafsson JA (June 1984). "Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin". Endocrinology. 114 (6): 2100–2106. doi:10.1210/endo-114-6-2100. PMID 6539197.
- ^ Pugeat MM, Dunn JF, Nisula BC (July 1981). "Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma". The Journal of Clinical Endocrinology and Metabolism. 53 (1): 69–75. doi:10.1210/jcem-53-1-69. PMID 7195405.
- ^ a b c d e Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 775–. ISBN 978-1-4757-2085-3.
- ^ a b c d e f g Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 656–. ISBN 978-3-88763-075-1.
- ^ Brooks JR, Primka RL, Berman C, Krupa DA, Reynolds GF, Rasmusson GH (August 1991). "Topical anti-androgenicity of a new 4-azasteroid in the hamster". Steroids. 56 (8): 428–433. doi:10.1016/0039-128x(91)90031-p. PMID 1788861. S2CID 21500107.
- ^ a b Carruthers M (2006). Androgen Deficiency in the Adult Male: Causes, Diagnosis and Treatment. CRC Press. pp. 137–178. ISBN 978-0-367-80018-5.
- ^ Neumann F, Wiechert R, Kramer M, Raspé G (April 1966). "[Experimental animal studies with a new androgen--mesterolone (1-alpha-methyl-5-alpha-androstan-17-beta-ol-one)]". Arzneimittel-Forschung (in German). 16 (4): 455–458. PMID 6014248.
- ^ Laschet U, Niermann H, Laschet L, Paarmann HF (1967). "Mesterolone, a potent oral active androgen without gonadotropin inhibition". Acta Endocrinologica. 56 (1_Suppl): S55. doi:10.1530/acta.0.056S055. ISSN 0804-4643.
- ^ Tausk M (1968). "Practically Applicable Results of Twenty Years of Research in Endocrinology". Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Vol. 12. pp. 137–164. doi:10.1007/978-3-0348-7065-8_3. ISBN 978-3-0348-7067-2. PMID 4307936.
{{cite book}}
:|journal=
ignored (help) - ^ a b Nieschlag E, Nieschlag S (2017). "The History of Testosterone and The Testes: From Antiquity to Modern Times". Testosterone. Springer. pp. 1–19. doi:10.1007/978-3-319-46086-4_1. ISBN 978-3-319-46084-0.
- ^ a b Hohl A (6 April 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 204–. ISBN 978-3-319-46086-4.
- ^ Kalinchenko S, Tyuzikov I, Mskhalaya G, Tishova Y (2017). "Testosterone Therapy: Oral Androgens". Testosterone. Springer. pp. 203–224. doi:10.1007/978-3-319-46086-4_10. ISBN 978-3-319-46084-0.
- ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 176–177. ISBN 978-94-011-4439-1.
- ^ a b c d "Mesterolone".
- ^ Lilley LL, Snyder JS, Collins SR (5 August 2016). Pharmacology for Canadian Health Care Practice. Elsevier Health Sciences. pp. 50–. ISBN 978-1-77172-066-3.
- ^ a b c Itil TM, Michael ST, Shapiro DM, Itil KZ (June 1984). "The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study)". Methods and Findings in Experimental and Clinical Pharmacology. 6 (6): 331–337. PMID 6431212.
- ^ a b Kövary PM, Lenau H, Niermann H, Zierden E, Wagner H (May 1977). "Testosterone levels and gonadotrophins in Klinefelter's patients treated with injections of mesterolone cipionate". Archives for Dermatological Research. 258 (3): 289–294. doi:10.1007/bf00561132. PMID 883846. S2CID 1222130.
Further reading
[edit]- Morrison MC (2000). Hormones, Gender and the Aging Brain: The Endocrine Basis of Geriatric Psychiatry. Cambridge, UK: Cambridge University Press. p. 134. ISBN 0-521-65304-5.
External links
[edit]- Proviron (mesterolone) - William Llewellyn's Anabolic.org Archived 2016-09-23 at the Wayback Machine.